Centanafadine is a multimodal norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI) that has been evaluated for the treatment of attention-deficit/hyperactivity disorder (ADHD) across pediatric, adolescent, and adult populations. This systematic review aimed to evaluate the efficacy, safety, and tolerability of centanafadine compared with placebo, with particular emphasis on dose-response patterns across different age groups. PubMed/MEDLINE, Embase, Scopus, and the Cochrane Central…
